News | January 18, 2024
NATCO invests US$ 2 million in Cellogen Therapeutics
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
Both these innovations are aimed at reducing the risk of relapse post CAR T cell therapy
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
CMOs showed an increasing reluctance to take on debt in 2022
SMPA's diverse portfolio includes six marketed products and a robust pipeline of early- to late-stage assets
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Acquisition will further strengthen Lonza’s bioconjugates offering through the integration of the industry-leading proprietary Synaffix technology platform and R&D capabilities, including payload and site-specific linker technology
The San Francisco facility is part of Thermo Fisher’s global pharma services network of more than 15 locations supporting cell and gene therapies.
All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
Subscribe To Our Newsletter & Stay Updated
